CSS
KERX

Cubist Systematic Strategies’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Cubist Systematic Strategies’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-100
Closed – – 2214
2018
Q2 		$0 Buy
+100
New +$487 ﹤0.01% 2203
2017
Q4 		– Sell
-23,040
Closed -$164K – 2214
2017
Q3 		$164K Sell
23,040
-2,302
-9% -$16.6K 0.01% 1516
2017
Q2 		$183K Buy
+25,342
New +$158K 0.01% 1325
2017
Q1 		– Sell
-1,409
Closed -$8K – 1995
2016
Q4 		$8K Buy
+1,409
New +$7.7K ﹤0.01% 1664
2016
Q2 		– Sell
-12,412
Closed -$58K – 1987
2016
Q1 		$58K Sell
12,412
-25,965
-68% -$104K ﹤0.01% 1463
2015
Q4 		$194K Buy
+38,377
New +$182K 0.01% 1369
2015
Q2 		– Sell
-2,000
Closed -$25K – 2175
2015
Q1 		$25K Buy
+2,000
New +$25.7K ﹤0.01% 1812
2014
Q3 		– Sell
-2,259
Closed -$35K – 1953
2014
Q2 		$35K Buy
+2,259
New +$32K ﹤0.01% 1433

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
PIMJS
PKO Investment Management Joint-Stock Warsaw, Poland $1.38B AUM 59.54% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cubist Systematic Strategies's KERX Position: Q3 2018 in Review

Cubist Systematic Strategies sold out of Keryx Biopharmaceuticals Inc (KERX) in Q3 2018, closing a stake of 100 shares.

Cubist Systematic Strategies first reported a position in KERX in Q2 2014 and held it in 8 quarters. The position peaked at $194K in Q4 2015. 123 funds tracked by Wall St. Rank hold KERX as of Q3 2018.

  • Cubist Systematic Strategies reported no remaining Keryx Biopharmaceuticals Inc position as of Q3 2018 after selling out during the quarter.
  • Cubist Systematic Strategies sold 100 Keryx Biopharmaceuticals Inc shares in Q3 2018.
  • Cubist Systematic Strategies first reported a position in Keryx Biopharmaceuticals Inc in Q2 2014 and held it in 8 quarters.
  • Cubist Systematic Strategies's Keryx Biopharmaceuticals Inc position peaked at $194K in Q4 2015.
  • 123 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q3 2018.

Based on Cubist Systematic Strategies's 13F filing for Q3 2018, filed 14 Nov 2018.